Human Leukocyte Antigen Testing Clause Samples
The Human Leukocyte Antigen (HLA) Testing clause establishes requirements and procedures for conducting HLA testing, which is used to determine tissue compatibility, often in the context of organ or bone marrow transplantation. This clause typically outlines who is responsible for arranging and paying for the testing, the standards or laboratories to be used, and the timeframe within which results must be provided. Its core function is to ensure that all parties have a clear understanding of how and when HLA testing will be performed, thereby reducing the risk of delays or disputes related to compatibility assessments.
Human Leukocyte Antigen Testing. This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.
Human Leukocyte Antigen Testing. In accordance with Rhode Island General Law §27-20-36, we cover human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime for utilization in bone marrow transplantation. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.
Human Leukocyte Antigen Testing. Human leukocyte antigen testing 0% - After deductible 20% - After deductible
Human Leukocyte Antigen Testing. To the extent that coverage for bone marrow or stem cell transplantation is more limited than the coverage required to be covered for "New Cancer Therapies," the applicable provisions of the Rhode Island Laws shall govern. See Section 7.0 for the definition of experimental/investigational services. When a doctor performs more than one procedure in a day, there are rules that may reduce our allowance for the additional procedure. Our allowance may also include post-operative care and other procedures provided within specified time periods. In addition to the type and purpose of surgery, our allowance differs depending on the number of surgeons involved, including assistant surgeons. If two (2) surgeons perform separate operations during a single surgical session, each surgeon may submit a claim reporting the procedure performed and the circumstances involved. These claims will then be evaluated for payment on an individual basis.
Human Leukocyte Antigen Testing. Human leukocyte antigen testing 20% - After Deductible 40% - After Deductible See Section 3.0 – Covered Health Care Services for additional benefit limits and coverage information. Inpatient/outpatient/in a doctor’s office Three (3) infertility treatment cycles will be covered per plan year with a total of eight (8) infertility treatment cycles covered in a member’s lifetime. 20% - After Deductible 20% - After Deductible Outpatient - hospital 20% - After Deductible 40% - After Deductible In the doctor’s office/in your home 20% - After Deductible 40% - After Deductible General hospital or specialty hospital services* Unlimited days 20% - After Deductible 40% - After Deductible Rehabilitation facility services* Limited to 45 days per plan year. 20% - After Deductible 40% - After Deductible Physician hospital visits 20% - After Deductible 40% - After Deductible